

# CURRICULUM VITAE

Family name: **RACCHI**  
First name: **MARCO**  
Date of birth: Nov 7<sup>th</sup> 1963  
Nationality: Italian  
Civil status: Married



## Education:

<i>Institution Degree(s) or Diploma(s) obtained:</i>	High school
<i>Date:</i>	1982
	Diploma
<i>Institution Degree(s) or Diploma(s) obtained:</i>	University of Milan, Italy
<i>Date:</i>	1989
	Degree in Pharmaceutical Chemistry and Technology
<i>Institution Degree(s) or Diploma(s) obtained:</i>	University of Milan, Italy
<i>Date:</i>	1997
	PhD in Biotechnology and Pharmacology

## Membership of professional bodies:

Member of the Italian Society of Pharmacology  
Member of the American Society of Neuroscience  
2009 - 2013. Administrative Board Member Università di Pavia  
2008-2010 Deputy director Dept. Experimental and Applied Pharmacology, Università di Pavia  
2011 - pres. Deputy Director Dept. of Drug Sciences, Director Section of Pharmacology.

**Present position:** Associate professor of Pharmacology (School of Pharmacy) at the Università degli Studi di Pavia, Italy

**Years within the organisation:** 18 years

## Key qualifications:

Current research activities are focused on two main field of research.

Alzheimer's disease: the activity is centered around the study of the pathogenetic mechanism of the disease with particular focus on the role of p53 and related signalling pathways in the sensitivity/resistance of neurons to cell death.

Aging and signal transduction: the activity is mainly focused to the study of the modulation of signalling pathways in aging specifically related to immune response and immunosenescence. In particular the laboratory is investigating the role of hormones (glucocorticoids and DHEA) in the modulation of signal transduction systems and the role of RACK1 and its signalling partners.

Marco Racchi is the author of more than 100 publications in peer-reviewed journals with a current citation record of more than 3000 and an H index of 31 (Google Scholar profile - <http://scholar.google.it/citations?user=YXPr0IAAAAAAJ&hl=en>)

### Professional Experience Record:

<b>Date:</b>	From 4/1990 to 4/1992
Location	USA (Winston Salem, NC)
Company	Wake Forest University Bowman Gray School of Medicine
Position	Post doctoral fellow
<b>Date:</b>	From 6/1993 to 8/1993
Location	USA (Winston Salem, NC)
Company	Wake Forest University Bowman Gray School of Medicine
Position	Visiting scientist
<b>Date:</b>	From 6/1995 to 8/1995
Location	USA (Winston Salem, NC)
Company	Wake Forest University Bowman Gray School of Medicine
Position	Visiting scientist
<b>Date:</b>	From 1996 to 1998
Location	Brescia (IT)
Company	IRCCS "Centro S. Giovanni di Dio - Fatebenefratelli"
Position	Research Scientist

### Publication record (selected 2009-2015)

1. Pinto A, Malacrida B, Oieni J, Serafini MM, Davin A, Galbiati V, Corsini E, Racchi M. Dhea Modulates the Effect of Cortisol on Rack1 Expression Via Interference with the Splicing of the Glucocorticoid Receptor. *Br J Pharmacol*. 2015 Jan 27.[Epub ahead of print]
2. Corsini E, Pinto A, Galbiati V, Viviani B, Galli CL, Marinovich M, Racchi M. Corticosteroids modulate the expression of the PKC-anchoring protein RACK-1 and cytokine release in THP-1 cells. *Pharmacol Res*. 2014 Mar;81:10-6.
3. Corsini E, Galbiati V, Esser PR, Pinto A, Racchi M, Marinovich M, Martin SF, Galli CL. Role of PKC- $\beta$  in chemical allergen-induced CD86 expression and IL-8 release in THP-1 cells. *Arch Toxicol*. 2014 Feb;88(2):415-24.
4. Govoni S, Mura E, Racchi M, Lanni C, Grilli M, Zappettini S, Salamone A, Olivero G, Pittaluga A, Marchi M. Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. *Curr Pharm Des*. 2014;20(15):2525-38.
5. Lanni C, Racchi M, Govoni S. Do we need pharmacogenetics to personalize antidepressant therapy? *Cell Mol Life Sci*. 2013 Sep;70(18):3327-40.
6. Buoso E, Biundo F, Lanni C, Aiello S, Grossi S, Schettini G, Govoni S, Racchi M. Modulation of Rack-1/PKC $\beta$ II signalling by soluble A $\beta$ PP $\alpha$  in SH-SY5Y cells. *Curr Alzheimer Res*. 2013 Sep;10(7):697-705.
7. Lanni C, Necchi D, Pinto A, Buoso E, Buizza L, Memo M, Uberti D, Govoni S, Racchi M. Zyxin is a novel target for  $\beta$ -amyloid peptide: characterization of its role in Alzheimer's pathogenesis. *J Neurochem*. 2013 Jun;125(5):790-9.
8. Buizza L, Prandelli C, Bonini SA, Delbarba A, Cenini G, Lanni C, Buoso E, Racchi M, Govoni S, Memo M, Uberti D. Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. *Cell Death Dis*. 2013 Feb 7;4:e484.
9. Stanga S, Lanni C, Sinfioriani E, Mazzini G, Racchi M. Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment. *Curr Alzheimer Res*. 2012 Dec;9(10):1191-7.

10. Lanni C, Racchi M, Memo M, Govoni S, Uberti D. p53 at the crossroads between cancer and neurodegeneration. *Free Radic Biol Med*. 2012 May 1;52(9):1727-33.
11. Buoso E, Biundo F, Lanni C, Schettini G, Govoni S, Racchi M. A $\beta$ PP intracellular C-terminal domain function is related to its degradation processes. *J Alzheimers Dis*. 2012;30(2):393-405.
12. Buizza L, Cenini G, Lanni C, Ferrari-Toninelli G, Prandelli C, Govoni S, Buoso E, Racchi M, Barcikowska M, Styczynska M, Szybinska A, Butterfield DA, Memo M, Uberti D. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. *PLoS One*. 2012;7(1):e29789.
13. Buoso E, Lanni C, Molteni E, Rousset F, Corsini E, Racchi M. Opposing effects of cortisol and dehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in immunosenescence. *Exp Gerontol*. 2011 Nov;46(11):877-83.
14. Schettini G, Govoni S, Racchi M, Rodriguez G. Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role--relevance for Alzheimer pathology. *J Neurochem*. 2010 Dec;115(6):1299-308.
15. Buoso E, Lanni C, Schettini G, Govoni S, Racchi M. beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. *Pharmacol Res*. 2010 Oct;62(4):308-17.
16. Stanga S, Lanni C, Govoni S, Uberti D, D'Orazi G, Racchi M. Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? *Aging (Albany NY)*. 2010 Sep;2(9):545-54. Review
17. Cenini G, Maccarinelli G, Lanni C, Bonini SA, Ferrari-Toninelli G, Govoni S, Racchi M, Butterfield DA, Memo M, Uberti D. Wild type but not mutant APP is involved in protective adaptive responses against oxidants. *Amino Acids*. 2010 Jun;39(1):271-83.
18. Lanni C, Nardinocchi L, Puca R, Stanga S, Uberti D, Memo M, Govoni S, D'Orazi G, Racchi M. Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. *PLoS One*. 2010 Apr 14;5(4):e10171.
19. Lanni C, Stanga S, Racchi M, Govoni S. The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. *Curr Pharm Des*. 2010;16(6):698-717. Review.
20. Mura E, Lanni C, Preda S, Pistoia F, Sarà M, Racchi M, Schettini G, Marchi M, Govoni S. Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? *Curr Pharm Des*. 2010;16(6):672-83. Review.
21. Lenzken SC, Stanga S, Lanni C, De Leonardis F, Govoni S, Racchi M. Recruitment of casein kinase 2 is involved in A $\beta$ PP processing following cholinergic stimulation. *J Alzheimers Dis*. 2010;20(4):1133-41.
22. Lanni C, Racchi M, Stanga S, Mazzini G, Ranzenigo A, Polotti R, Memo M, Govoni S, Uberti D. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease. *J Alzheimers Dis*. 2010;20(1):97-104.
23. Salvioli S, Capri M, Bucci L, Lanni C, Racchi M, Uberti D, Memo M, Mari D, Govoni S, Franceschi C. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. *Cancer Immunol Immunother*. 2009 Dec;58(12):1909-17.
24. Del Vecchio I, Zuccotti A, Pisano F, Caneva F, Lenzken SC, Rousset F, Corsini E, Govoni S, Racchi M. Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein. *Gene*. 2009 Feb 1;430(1-2):17-29.
25. Corsini E, Racchi M, Lucchi L, Donetti E, Bedoni M, Viviani B, Galli CL, Marinovich M. Skin immunosenescence: decreased receptor for activated C kinase-1 expression correlates with defective tumour necrosis factor-alpha production in epidermal cells. *Br J Dermatol*. 2009 Jan;160(1):16-25.

**Contact Address:**

Prof. Marco Racchi

Department of Drug Sciences - Pharmacology Unit

Viale Taramelli 14

27100 Pavia, Italy

Phone +39 0382 987738

Mobile Phone +39 340 7827919

FAX +39 0382 987405

e-mail: [racchi@unipv.it](mailto:racchi@unipv.it)